{"markup":"\u003C?xml version=\u00221.0\u0022 encoding=\u0022UTF-8\u0022 ?\u003E\n    \u003Chtml version=\u0022HTML+RDFa+MathML 1.1\u0022\n    xmlns:content=\u0022http:\/\/purl.org\/rss\/1.0\/modules\/content\/\u0022\n    xmlns:dc=\u0022http:\/\/purl.org\/dc\/terms\/\u0022\n    xmlns:foaf=\u0022http:\/\/xmlns.com\/foaf\/0.1\/\u0022\n    xmlns:og=\u0022http:\/\/ogp.me\/ns#\u0022\n    xmlns:rdfs=\u0022http:\/\/www.w3.org\/2000\/01\/rdf-schema#\u0022\n    xmlns:sioc=\u0022http:\/\/rdfs.org\/sioc\/ns#\u0022\n    xmlns:sioct=\u0022http:\/\/rdfs.org\/sioc\/types#\u0022\n    xmlns:skos=\u0022http:\/\/www.w3.org\/2004\/02\/skos\/core#\u0022\n    xmlns:xsd=\u0022http:\/\/www.w3.org\/2001\/XMLSchema#\u0022\n    xmlns:mml=\u0022http:\/\/www.w3.org\/1998\/Math\/MathML\u0022\u003E\n  \u003Chead\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_itu2PgFdrjV-docKmLK8Jn5oXe_05RgvQh73eOhI_mE.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_at_symbol.js?nznhip\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_article_reference_popup.js?nznhip\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/js\/js_I8yX6RYPZb7AtMcDUA3QKDZqVkvEn35ED11_1i7vVpc.js\u0022\u003E\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\n(function(i,s,o,g,r,a,m){i[\u0022GoogleAnalyticsObject\u0022]=r;i[r]=i[r]||function(){(i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)})(window,document,\u0022script\u0022,\u0022\/\/www.google-analytics.com\/analytics.js\u0022,\u0022ga\u0022);ga(\u0022create\u0022, \u0022UA-15605596-27\u0022, {\u0022cookieDomain\u0022:\u0022auto\u0022});ga(\u0022set\u0022, \u0022page\u0022, location.pathname + location.search + location.hash);ga(\u0022send\u0022, \u0022pageview\u0022);ga(\u0027create\u0027, \u0027UA-189672-26\u0027, \u0027auto\u0027, {\u0027name\u0027: \u0027hwTracker\u0027});\r\nga(\u0027hwTracker.send\u0027, \u0027pageview\u0027);\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Cscript type=\u0022text\/javascript\u0022\u003E\n\u003C!--\/\/--\u003E\u003C![CDATA[\/\/\u003E\u003C!--\njQuery.extend(Drupal.settings, {\u0022basePath\u0022:\u0022\\\/\u0022,\u0022pathPrefix\u0022:\u0022\u0022,\u0022highwire\u0022:{\u0022markup\u0022:[{\u0022requested\u0022:\u0022full-text\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/4\\\/22\u0022},{\u0022requested\u0022:\u0022long\u0022,\u0022variant\u0022:\u0022full-text\u0022,\u0022view\u0022:\u0022full\u0022,\u0022pisa\u0022:\u0022spmdc;12\\\/4\\\/22\u0022}],\u0022ac\u0022:{\u0022spmdc;12\\\/4\\\/22\u0022:{\u0022access\u0022:{\u0022reprint\u0022:true,\u0022full\u0022:true},\u0022pisa_id\u0022:\u0022spmdc;12\\\/4\\\/22\u0022,\u0022atom_uri\u0022:\u0022\u0022,\u0022jcode\u0022:\u0022spmdc\u0022}}},\u0022googleanalytics\u0022:{\u0022trackOutbound\u0022:1,\u0022trackMailto\u0022:1,\u0022trackDownload\u0022:1,\u0022trackDownloadExtensions\u0022:\u00227z|aac|arc|arj|asf|asx|avi|bin|csv|doc(x|m)?|dot(x|m)?|exe|flv|gif|gz|gzip|hqx|jar|jpe?g|js|mp(2|3|4|e?g)|mov(ie)?|msi|msp|pdf|phps|png|ppt(x|m)?|pot(x|m)?|pps(x|m)?|ppam|sld(x|m)?|thmx|qtm?|ra(m|r)?|sea|sit|tar|tgz|torrent|txt|wav|wma|wmv|wpd|xls(x|m|b)?|xlt(x|m)|xlam|xml|z|zip\u0022,\u0022trackUrlFragments\u0022:1},\u0022ajaxPageState\u0022:{\u0022js\u0022:{\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/jquery.cluetip.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.hoverIntent.js\u0022:1,\u0022sites\\\/all\\\/libraries\\\/cluetip\\\/lib\\\/jquery.bgiframe.min.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_at_symbol.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/highwire\\\/highwire\\\/plugins\\\/highwire_markup_process\\\/js\\\/highwire_article_reference_popup.js\u0022:1,\u0022sites\\\/all\\\/modules\\\/contrib\\\/google_analytics\\\/googleanalytics.js\u0022:1,\u00220\u0022:1}}});\n\/\/--\u003E\u003C!]]\u003E\n\u003C\/script\u003E\n\u003Clink type=\u0022text\/css\u0022 rel=\u0022stylesheet\u0022 href=\u0022\/\/d282kpwvnogo5m.cloudfront.net\/sites\/default\/files\/advagg_css\/css__ce2QY63WIanKyr8eSq7eavr1XQRRmFD6ZSmwpyJi8lM__zXwFqpqmxrZOXXcd_TpBQpjuELbmIP9wBR5UuTDWAO4__YJWWMMdfCJuAFm5cUEp88OsodhO3ZA-2lzRfoBsSlk4.css\u0022 media=\u0022all\u0022 \/\u003E\n\u003Clink rel=\u0027stylesheet\u0027 type=\u0027text\/css\u0027 href=\u0027\/sites\/all\/modules\/contrib\/panels\/plugins\/layouts\/onecol\/onecol.css\u0027 \/\u003E\u003C\/head\u003E\u003Cbody\u003E\u003Cdiv class=\u0022panels-ajax-tab-panel panels-ajax-tab-panel-sageoa-tab-art\u0022\u003E\u003Cdiv class=\u0022panel-display panel-1col clearfix\u0022 \u003E\n  \u003Cdiv class=\u0022panel-panel panel-col\u0022\u003E\n    \u003Cdiv\u003E\u003Cdiv class=\u0022panel-pane pane-highwire-markup\u0022 \u003E\n  \n      \n  \n  \u003Cdiv class=\u0022pane-content\u0022\u003E\n    \u003Cdiv class=\u0022highwire-markup\u0022\u003E\u003Cdiv xmlns=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022 id=\u0022content-block-markup\u0022 xmlns:xhtml=\u0022http:\/\/www.w3.org\/1999\/xhtml\u0022\u003E\u003Cdiv class=\u0022article fulltext-view \u0022\u003E\u003Cspan class=\u0022highwire-journal-article-marker-start\u0022\u003E\u003C\/span\u003E\u003Cdiv class=\u0022section abstract\u0022 id=\u0022abstract-1\u0022\u003E\u003Ch2\u003ESummary\u003C\/h2\u003E\n            \u003Cp id=\u0022p-1\u0022\u003ECell therapy has emerged as an exciting and innovative approach for treating patients with advanced ischemic heart disease, including those with refractory angina and\/or heart failure [Perin EC et al. \u003Cem\u003EJAMA\u003C\/em\u003E 2012]. The FOCUS-CCTRN trial [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00824005\u0026amp;atom=%2Fspmdc%2F12%2F4%2F22.atom\u0022\u003ENCT00824005\u003C\/a\u003E] was designed to evaluate the safety and efficacy of bone marrow mononuclear cells in patients with chronic ischemic heart disease and left ventricular dysfunction with no other revascularization options.\u003C\/p\u003E\n         \u003C\/div\u003E\u003Cul class=\u0022kwd-group\u0022\u003E\u003Cli class=\u0022kwd\u0022\u003ECoronary Artery Disease\u003C\/li\u003E\u003Cli class=\u0022kwd\u0022\u003EClinical Trials Genomics\u003C\/li\u003E\u003C\/ul\u003E\u003Cp id=\u0022p-2\u0022\u003ECell therapy has emerged as an exciting and innovative approach for treating patients with advanced ischemic heart disease, including those with refractory angina and\/or heart failure [Perin EC et al. \u003Cem\u003EJAMA\u003C\/em\u003E 2012]. The FOCUS\u2013CCTRN trial [\u003Ca class=\u0022external-ref external-ref-type-clintrialgov\u0022 href=\u0022\/lookup\/external-ref?link_type=CLINTRIALGOV\u0026amp;access_num=NCT00824005\u0026amp;atom=%2Fspmdc%2F12%2F4%2F22.atom\u0022\u003ENCT00824005\u003C\/a\u003E] was designed to evaluate the safety and efficacy of bone marrow mononuclear cells (BMCs) in patients with chronic ischemic heart disease and left ventricular (LV) dysfunction with no other revascularization options. Emerson Perin, MD, PhD, Texas Heart Institute, St. Luke\u0027s Episcopal Hospital, Houston, Texas, USA, presented data from the study, the largest to date on autologous bone marrow therapy in patients with chronic ischemic heart disease.\u003C\/p\u003E\u003Cp id=\u0022p-3\u0022\u003EPrior smaller studies had suggested that BMCs would provide benefit for patients with ischemic cardiomyopathy. The primary objective of FOCUS\u2013CCTRN was to determine if transendocardial administration of 100 \u00d7 10\u003Csup\u003E6\u003C\/sup\u003E total BMCs improved measures of LV performance and perfusion at 6 months compared with baseline levels. Coprimary endpoints included left ventricular end systolic volume (LVESV), maximal oxygen consumption (MVO\u003Csub\u003E2\u003C\/sub\u003E), and change in ischemic (reversible) defect size.\u003C\/p\u003E\u003Cp id=\u0022p-4\u0022\u003EThe study enrolled symptomatic patients (NYHA classification III or Canadian Cardiovascular Society classification II\u2013IV) with a LV ejection fraction (LVEF) \u226445% a perfusion defect by SPECT, and coronary artery disease that was not amenable to revascularization. All were receiving maximal medical therapy at five National Heart, Lung, and Blood Institute\u2013sponsored Cardiovascular Cell Therapy Research Network (CCTRN) sites between April 29, 2009 and April 18, 2011.\u003C\/p\u003E\u003Cp id=\u0022p-5\u0022\u003EA total of 92 patients (82 men; average age 63 years) were randomized (n=61 in the BMC group and n=31 in the placebo group) to receive bone marrow aspiration and transendocardial injection of 100 \u00d7 10\u003Csup\u003E6\u003C\/sup\u003E bone marrow cells or placebo.\u003C\/p\u003E\u003Cp id=\u0022p-6\u0022\u003EChanges in LV end systolic volume index (\u22120.9 mL\/m\u003Csup\u003E2\u003C\/sup\u003E [95% CI, \u22126.1 to 4.3]; p=0.73), maximal oxygen consumption (1.0 [95% CI, \u22120.42 to 2.34]; p=0.17), and the difference in the change for percent reversible defect (\u22121.2 [95% CI, \u221212.5 to 10.12]; p=0.84) were not statistically significant. No differences were observed in any of the secondary outcomes, including percent myocardial defect, total defect size, regional wall motion, and clinical improvement.\u003C\/p\u003E\u003Cp id=\u0022p-7\u0022\u003EAn exploratory analyses revealed that LVEF improved in the BMC group compared with the placebo group (+1.4 vs \u22121.3; p=0.030). LVEF improvement was observed in patients who were younger than the median study population age and correlated with the percentage of CD34+ and CD133+ cells in bone marrow samples. A prespecified analysis of cell function (ECFC) also showed significant improvement in MV0\u003Csub\u003E2\u003C\/sub\u003E in patients with higher\u2013than\u2013median ECFC values.\u003C\/p\u003E\u003Cp id=\u0022p-8\u0022\u003EDr. Perin concluded that evaluation of the inherent variability in the cell product may provide mechanistic insights and help select patients who are likely to benefit from autologous cell therapy. He said that additional analyses of cell function will be forthcoming from the CCTRN biorepository and should help guide the design of future clinical trials in patients with ischemic heart disease and LV dysfunction.\u003C\/p\u003E\u003Cp id=\u0022p-9\u0022\u003EThe lack of efficacy that was observed in the primary and secondary results is disappointing for this highly anticipated therapy. It is possible that prior smaller studies overestimated the efficacy or that the characteristics of the cell population or delivery system were not optimal in FOCUS\u2013CCTRN. Additional analyses from this study will be helpful in guiding future trials of cell therapy.\u003C\/p\u003E\u003Cul class=\u0022copyright-statement\u0022\u003E\u003Cli class=\u0022fn\u0022 id=\u0022copyright-statement-1\u0022\u003E\u00a9 2012 MD Conference Express\u00ae\u003C\/li\u003E\u003C\/ul\u003E\u003Cspan class=\u0022highwire-journal-article-marker-end\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Cspan id=\u0022related-urls\u0022\u003E\u003C\/span\u003E\u003C\/div\u003E\u003Ca href=\u0022http:\/\/mdc.sagepub.com\/content\/12\/4\/22.abstract\u0022 class=\u0022hw-link hw-link-article-abstract\u0022 data-icon-position=\u0022\u0022 data-hide-link-title=\u00220\u0022\u003EView Summary\u003C\/a\u003E\u003C\/div\u003E  \u003C\/div\u003E\n\n  \n  \u003C\/div\u003E\n\u003C\/div\u003E\n  \u003C\/div\u003E\n\u003C\/div\u003E\n\u003C\/div\u003E\u003Cscript type=\u0022text\/javascript\u0022 src=\u0022http:\/\/mdc.sagepub.com\/sites\/all\/modules\/highwire\/highwire\/plugins\/highwire_markup_process\/js\/highwire_openurl.js?nznhip\u0022\u003E\u003C\/script\u003E\n\u003C\/body\u003E\u003C\/html\u003E"}